سعر فيلكاد Velcade‏ 1مجم فيال للحقن الوريدي 2026

Velcade (bortezomib) 1 mg powder in vial for injection (Janssen-Cilag; Egyptian distributor Sofico Pharm).

• Most common (>=20%): nausea, diarrhoea, thrombocytopenia, neutropenia, peripheral neuropathy, fatigue, neuralgia, anaemia, leukopenia, constipation, vomiting, lymphopenia, rash, pyrexia and anorexia.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Contraindicated in hypersensitivity (not including local reactions) to bortezomib, boron or mannitol, and for intrathecal administration (fatal events reported).International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Peripheral neuropathy: manage with dose modification or discontinuation.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)
• Hypotension, cardiac toxicity, pulmonary toxicity, posterior reversible encephalopathy syndrome, gastrointestinal toxicity, tumour lysis syndrome, hepatic toxicity and thrombotic microangiopathy have been reported.International label, equivalent formulation · DailyMed (U.S. National Library of Medicine)

• Strong CYP3A4 inducersDecrease bortezomib exposure; avoid coadministration.DailyMed (U.S. National Library of Medicine)
• Strong CYP3A4 inhibitorsClosely monitor patients with concomitant use.DailyMed (U.S. National Library of Medicine)

• Bortezomib: Reversible inhibitor of the chymotrypsin-like activity of the 26S proteasome.